| *Sponsored
Nasdaq MedTech Profile (INBS) Is A Low Float Idea With A Strong Analyst Target
May 13th Greetings, Friend!
Let's rewind to this past Friday in case you weren't around...
Pay close attention-because the action with my latest Nasdaq profile was nothing short of electrifying.
Following Thursday’s after-hours close of $.54, that sizzler rocketed to a Friday high of $.8138, setting the market abuzz.
We’re talking about a lightning-fast surge of approx. 50% in a matter of hours-an explosive move that left profile trackers looking for more.
But here’s where it gets even more exciting: I’ve got my eye on a brand-new, under-the-radar profile.
With a low float of fewer than 5Mn shares, a $12 analyst target suggesting over 850% potential upside from Monday's close, and massive May news, this Nasdaq profile may start earning Wall Street's immediate attention.
Consider taking a look at: Intelligent Bio Solutions Inc. (Nasdaq: INBS)
Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide.
With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies.
Company Overview
Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life.
The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety.
Core Technologies and Products
Intelligent Fingerprinting Drug Testing Solution
At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution.
This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours.
The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes.
Key advantages include:
- Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns.
- Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings.
- Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required.
- Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use.
Regulatory Milestones And U.S. Market Entry
A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024.
The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection.
INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2025, targeting a region that accounts for approximately 28% of the global drug screening market.
The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS.
Intellectual Property and Competitive Position
INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design.
This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development.
Market Opp. And Future Outlook | 
0 Response to "Nasdaq MedTech Profile (INBS) Is A Low Float Idea With A Strong Analyst Target"
Post a Comment